arsenic trioxide has been researched along with valsartan in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chandrabhatla, AS; Christiansen, SL; Holmes, JW; Nelson, AR; Saucerman, JJ; Zeigler, AC | 1 |
1 review(s) available for arsenic trioxide and valsartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for arsenic trioxide and valsartan
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Arsenic Trioxide; Biphenyl Compounds; Computer Simulation; Drug Combinations; Fibroblasts; Fibrosis; Heart Diseases; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Models, Animal; Network Pharmacology; Pyrazoles; Quaternary Ammonium Compounds; Quinolines; Rats; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad3 Protein; Thioctic Acid; Valsartan | 2021 |